How would defining Parkinson’s as a prion disease impact the search of a cure?

References

• Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994;345(1):27–32.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med. 2008;14:504–506.
   PubMed Web of Science ®Google Scholar
• Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med. 2008;14:501–503.
   PubMed Web of Science ®Google Scholar
• Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009;106:13010–13015.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Prusiner SB. Is Parkinson’s disease a prion disorder? Proc Natl Acad Sci U S A. 2009;106:12571–12572.
   PubMed Web of Science ®Google Scholar
• Luk KC, Song C, O’Brien P, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009;106:20051–20056.
   PubMed Web of Science ®Google Scholar
• Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain. 2013;136:1128–1138.
   PubMed Web of Science ®Google Scholar
• Moore RA, Taubner LM, Priola SA. Prion protein misfolding and disease. Curr Opin Struct Biol. 2009;19(1):14–22.
   PubMed Web of Science ®Google Scholar
• Smethurst P, Sidle KC, Hardy J. Review: prion-like mechanisms of transactive response DNA binding protein of 43 kDa (TDP-43) in amyotrophic lateral sclerosis (ALS). Neuropathol Appl Neurobiol. 2015;41:578–597.
   PubMed Web of Science ®Google Scholar
• Holmes BB, Diamond MI. Amyotrophic lateral sclerosis and organ donation: is there risk of disease transmission? Ann Neurol. 2012;72:832–836.
   PubMed Web of Science ®Google Scholar
• Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:532–540.
   PubMed Web of Science ®Google Scholar
• Peelaerts W, Bousset L, Van der Perren A, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522:340–344.
   PubMed Web of Science ®Google Scholar
• Lau A, So JC, Lau HH, et al. α-Synuclein strains target distinct brain regions and cell types. Nat Neurosci. 2020;23(1):21–31. .
   PubMed Web of Science ®Google Scholar
• Scialo C, De Cecco E, Manganotti P, et al. Prion and prion-like protein strains: deciphering the molecular basis of heterogeneity in neurodegeneration. Viruses. 2019;11(3):261.
   PubMed Web of Science ®Google Scholar
• Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: the dual hit theory revisited. Ann N Y Acad Sci. 2009;1170:615–622.
   PubMed Web of Science ®Google Scholar
• Kim S, Kwon SH, Kam TI, et al. Transneuronal propagation of pathologic alpha-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103:627–641 e7.
   PubMed Web of Science ®Google Scholar
• De Luca CMG, Elia AE, Portaleone SM, et al. Efficient RT-QuIC seeding activity for alpha-synuclein in olfactory mucosa samples of patients with Parkinson’s disease and multiple system atrophy. Transl Neurodegener. 2019;8:24.
   PubMed Web of Science ®Google Scholar
• Chen H, Burton EA, Ross GW, et al. Research on the premotor symptoms of Parkinson’s disease: clinical and etiological implications. Environ Health Perspect. 2013;121:1245–1252.
   PubMed Web of Science ®Google Scholar
• Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord. 2006;21:2062–2067.
   PubMed Web of Science ®Google Scholar
• Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 2008;63:167–173.
   PubMed Web of Science ®Google Scholar
• Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007;22:1581–1586.
   PubMed Web of Science ®Google Scholar
• Gao X, Chen H, Schwarzschild MA, et al. A prospective study of bowel movement frequency and risk of Parkinson’s disease. Am J Epidemiol. 2011;174:546–551.
   PubMed Web of Science ®Google Scholar
• Svensson E, Horvath-Puho E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. 2015;78:522–529.
   PubMed Web of Science ®Google Scholar
• Masuda M, Suzuki N, Taniguchi S, et al. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry. 2006;45:6085–6094.
   PubMed Web of Science ®Google Scholar
• Latawiec D, Herrera F, Bek A, et al. Modulation of alpha-synuclein aggregation by dopamine analogs. PLoS One. 2010;5:e9234.
   PubMed Web of Science ®Google Scholar
• De Cecco E, Legname G. The role of the prion protein in the internalization of alpha-synuclein amyloids. Prion. 2018;12:23–27.
   PubMed Web of Science ®Google Scholar
• Aulic S, Masperone L, Narkiewicz J, et al. Alpha-synuclein amyloids hijack prion protein to gain cell entry, facilitate cell-to-cell spreading and block prion replication. Sci Rep. 2017;7:10050.
   PubMed Web of Science ®Google Scholar
• Shahnawaz M, Mukherjee A, Pritzkow S, et al. Discriminating alpha-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020;578:273–277.
   PubMed Web of Science ®Google Scholar
• George S, Brundin P. Immunotherapy in Parkinson’s Disease: micromanaging alpha-synuclein aggregation. J Parkinsons Dis. 2015;5:413–424.
   PubMedGoogle Scholar
• Wang Z, Gao G, Duan C, et al. Progress of immunotherapy of anti-alpha-synuclein in Parkinson’s disease. Biomed Pharmacother. 2019;115:108843.
   PubMed Web of Science ®Google Scholar
• Walker LC, Jucker M. Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci. 2015;38:87–103.
   PubMed Web of Science ®Google Scholar